IART earnings

PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026. First Quarter 2026 Highlights First quarter revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.06), compared to $(0.33) in the prior year. Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year.Reaffirming 2026 full year revenue guidance of $1.662 billion to $1.702 billion and updating 2026 adjusted earnings

Stuart Essig Appointed as Integra's Next President and Chief Executive OfficerMichael McBreen Appointed Chief Commercial Officer PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART), a leading global medical technology company, today announced that Stuart M. Essig, chairman of Integra's Board of Directors (the "Board"), has been appointed president and chief executive officer, effective May 1, 2026. Mr. Essig will continue to serve as chairman. He succeeds Mojdeh Poul who is pursuing other opportunities. The Company also announced that Michael McBreen, currently executive vice president, president, Codman S

PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the con

PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) --  Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted share were $0.83, compared to $0.97 in the fourth quarter of 2024. Full-Year 2025 Reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and

PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webc

PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year. Third quarter GAAP earnings per diluted share of $(0.07), compared to $(0.14) in the prior year. Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year.Relaunch of PriMatrix® and Durepair® ahead of schedule, through dual sourcing supply strategy.Appointed Dr. Raymond Tur

PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of th

PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $(6.31), compared to $(0.16) in the prior year primarily reflecting a goodwill impairment charge of $511 million, recorded during t

PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conf

PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per diluted share were $0.97, compared to $0.89 in the fourth quarter 2023. Full-Year 2024 Reported revenues were $1,610.5 million, representing an increase of 4.5% on a reported basis and

PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A w

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Highlights Third quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased 10.3% on an organic basis excluding Boston.Third quarter GAAP earnings per diluted share of $(0.14), compared to $0.24 in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.76 in the prior year.Shipping holds communicated during the second quarter ea

PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2024. Second Quarter 2024 Highlights Second quarter revenues of $418.2 million increased 9.7% on a reported basis and 2.3% on an organic basis compared to the prior year. Revenue increased 0.3% on an organic basis excluding Boston.Second quarter GAAP earnings per diluted share of $(0.16), compared to $0.05 in the prior year; adjusted earnings per diluted share of $0.63, compared to $0.71 in the prior year.Early integration success with the Acclarent ENT a

PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2024 financial results on Monday, July 29, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the co

PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 Highlights First quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis excluding BostonFirst quarter GAAP earnings per diluted share of $(0.04), compared to $0.29 in the prior year; adjusted earnings per diluted share of $0.55, compared to $0.74 in the prior yearCompleted the acquisition of the Acclarent, Inc. on April 1

PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company's first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. EDT. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommende

PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent's innovative product portfolio expands the breadth of Integra's market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel. The acquisition adds $1 billion to the total addressable market of the Company's offerings, while providing unique market opportunities for access to the attractive ENT device segment. "Acclarent's stro

PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Reported revenues were $397.0 million, representing a decrease of 0.2% on a reported basis and a decrease of 1.2% on an organic basis compared to the fourth quarter 2022. Revenue increased 3.6% on an organic basis excluding Boston. GAAP earnings per diluted share were $0.25, compared to $0.63 in the fourth quarter 2022. Adjusted earnings per diluted share were $0.89, compared to $0.94 in the fourth quarter of 2022. Full-Year 2023 Reported revenues were $1,541.6 mill

Jan De Witte to retire as CEO by the end of 2024Stuart Essig appointed executive chairman of the Board PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or "the Company") (NASDAQ:IART), a leading global medical technology company, today announced that Jan De Witte has informed the Board of Directors (the "Board") of his intention to retire from his position as president and chief executive officer of Integra following the appointment of a successor, which the Company expects to occur by the end of 2024. The Company also announced that Stuart Essig, Integra's chairman, has been appointed to the role of executive chairman, effective

PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A web

The acquisition will become part of Integra's Codman Specialty Surgical (CSS) division. The ear, nose and throat (ENT) category is a key area of strategic interest and highly complementary to the neurosurgery segment.Provides a unique opportunity to build scale and capture a leadership position in the attractive ENT device segment with Acclarent's established commercial scale, strong brand recognition, differentiated portfolio, and robust innovation pipeline.    Generates shareholder value; transaction expected to be accretive to Integra's long-range plan. PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a global leader in medical

PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023. Third Quarter 2023 Highlights Third quarter revenues of $382.4 million declined 0.7% on a reported basis and declined 0.4% on an organic basis compared to the prior year and increased 7.1% on an organic basis excluding BostonThird quarter GAAP earnings per diluted share of $0.24, compared to $0.60 in the prior year; adjusted earnings per diluted share of $0.76, compared to $0.86 in the prior yearSuccessfully completed all interim external inspections in pre

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2023 financial results on Wednesday, October 25, 2023, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of

PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2023. Second Quarter 2023 Highlights Second quarter revenues of $381.3 million declined 4.2% on a reported basis and declined 2.7% on an organic basis compared to the prior year. Second quarter GAAP earnings per diluted share of $0.05, compared to $0.54 in the prior year; adjusted earnings per diluted share of $0.71, compared to $0.82 in the prior year Appointed Lea Daniels Knight as executive vice president and CFO Share repurchase and 2023 guidance Planning a $

PRINCETON, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2023 financial results on Thursday, July 27, 2023, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of th

PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2023. First Quarter 2023 Highlights First quarter revenues of $380.8 million increased 1.1% on a reported basis and increased 4.6% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $0.29, compared to $0.39 in the prior year; adjusted earnings per diluted share of $0.74, compared to $0.74 in the prior year.The Company is reaffirming its full-year 2023 revenue and adjusted earnings per share guidance with a range of $1,60

PRINCETON, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2023 financial results on Wednesday, April 26, 2023, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, it is recommended to join 10 minutes prior to the event's start. A webcast replay

PRINCETON, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2022, consistent with its preliminary financial results announced on January 10, 2023 and January 25, 2023.        Fourth Quarter 2022 Reported revenues were $398.0 million, representing a decrease of 1.8% on a reported basis and an increase of 2.9% on an organic basis compared to the fourth quarter 2021. GAAP earnings per diluted share were $0.63, compared to $0.53 in the fourth quarter 2021. Adjusted earnings per diluted share were $0.94, compared to $0.84 in the fourth quarter of 2021. Ful

PRINCETON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter 2022 financial results on Wednesday, February 22, 2023, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event's start. A webcast replay

Fourth Quarter 2022  Fourth quarter 2022 revenue is expected to be in a range of $397 million to $398 million, representing a decrease of approximately 2% on a reported basis and an increase of approximately 3% on an organic basis compared to 2021. Fourth quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company's October guidance range. Full-Year 2022  Full-year 2022 revenue is expected to be in a range of $1,557 million to $1,558 million, representing an increase of approximately 1% on a reported basis and an increase of approximately 4% on an organic basis compared to 2021.Full-year quarter 2022 adjusted earnings per diluted share is expected

PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2022. Third Quarter 2022 Highlights Third quarter revenues of $385 million decreased 0.4% on a reported basis and increased 3.5% on an organic basis compared to the prior year. Third quarter GAAP earnings per diluted share of $0.60, compared to $0.51 in the prior year; adjusted earnings per diluted share of $0.86, compared to $0.86 in the prior year.The Company completed the sale of its non-core traditional wound care ("TWC") business at the end of August 2022.Th

PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2022 financial results on Wednesday, October 26, 2022, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. The live call is accessible by dialing 866-571-0905 and using the passcode 1121226#. A simultaneous webcast of the call will be available via the Company's website at www.integralife.com. A webcast replay of the call can be accessed through the Investor Relations homepage of Integra's website at www.integralife.com. A re

PRINCETON, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2022. Second Quarter 2022 Highlights Second quarter revenues of $398 million increased 2.0% on a reported basis and 4.8% on an organic basis compared to the prior year. Six-month revenues for 2022 were $774 million and increased 3.3% on a reported basis and 5.2% on an organic basis compared to the prior year. Second quarter GAAP earnings per diluted share of $0.54, compared to $0.41 in the prior year; adjusted earnings per diluted share of $0.82, compared to $0.79

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- )Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2022 financial results on Wednesday, July 27, 2022, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. The live call is accessible by dialing 800-289-0720 and using the passcode 2688312. A simultaneous webcast of the call will be available via the Company's website at www.integralife.com. A webcast replay of the call can be accessed through the Investor Relations homepage of Integra's website at www.integralife.com. A repl

PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2022. First Quarter 2022 Highlights Revenues of $376.6 million increased 4.6% on a reported basis and 5.6% on an organic basis compared to the prior year.GAAP earnings per diluted share of $0.39, compared to $0.53 in the first quarter of 2021; adjusted earnings per diluted share of $0.74, compared to $0.69 in the prior year.The Company is raising its previous full-year 2022 organic growth guidance of 3.5% to 5% to a new range of 3.8% to 5.2%, reflecting the better t

PRINCETON, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2022 financial results on Wednesday, April 27, 2022, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. The live call is accessible by dialing (800)-289-0720 and using the passcode 5706502. A simultaneous webcast of the call will be available via the Company's website at www.integralife.com. A webcast replay of the call can be accessed through the Investor Relations homepage of Integra's website at www.integralife.com. A re

PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2021, consistent with its preliminary revenue results announced on January 11, 2022. Fourth Quarter 2021 Reported revenues were $405.5 million, representing an increase of 4.3% on a reported basis and an increase of 8.3% on an organic basis compared to the fourth quarter 2020. GAAP earnings per diluted share were $0.53, compared to $1.09 in the fourth quarter 2020.Adjusted earnings per diluted share were $0.84, flat compared to the fourth quarter of 2020. Full-Year 2021 Reported revenues were

Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year.Full-year 2021 revenue is expected to be in a range of $1,541 million to $1,543 million, representing an increase of approximately 12% on a reported basis and an increase of approximately 14% on an organic basis compared to the prior year.The company is planning a $125 million share repurchase as a part of a previous approval by the Board of Directors, with an authorization of up to $225 million. PRINCETON, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Integra

Third Quarter 2021 Highlights Revenues of $386.9 million increased 4.5% on a reported basis and 6.7% on an organic basis compared to the prior year;GAAP earnings per diluted share of $0.51, compared to $0.38 in the third quarter of 2020; adjusted earnings per diluted share of $0.86, compared to $0.80 in the prior year;Cash flow from operations of $82.8 million increased 18.9% from the prior year;The Company is reaffirming its previous full-year 2021 revenue guidance of $1,540 million to $1,550 million, with an expectation to be at the low end of the range. The Company is raising its full-year 2021 adjusted earnings per share guidance range from $2.98 to $3.05 to a new range of $3.16 to $3

PRINCETON, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2021 financial results on Tuesday, November 2, 2021, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. The live call is accessible by dialing (888) 394-8218 and using the passcode 7732018. A simultaneous webcast of the call will be available via the Company's website at www.integralife.com. A webcast replay of the call can be accessed through the Investor Relations homepage of Integra's website at www.integralife.com. A re

Second Quarter 2021 Highlights Revenues of $390.0 million increased 50.8% on a reported basis and 48.7% on an organic basis compared to the prior year;GAAP earnings per diluted share of $0.41, compared to $(0.00) in the second quarter of 2020; adjusted earnings per diluted share of $0.79, compared to $0.33 in the prior year;Cash flow from operations of $91.3 million increased 176% from the prior year;Raising full-year 2021 revenue guidance by $15 million to a range of $1,540 million to $1,550 million and adjusted earnings per share to a range of $2.98 to $3.05. PRINCETON, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global med